Name: CJC-1295 5mg
SKU: 16197
Availability: InStock

Description

Mod GRF 1-29 (CJC-1295 no DAC) Description

Mod GRF 1-29 is a research-grade synthetic analog of growth hormone-releasing hormone designed for laboratory investigations. This modified peptide features four strategic amino acid substitutions that enhance stability against enzymatic degradation compared to native GRF sequences.

Manufactured in USA facilities under research-grade standards and verified through independent third-party testing. Each batch undergoes rigorous quality control to ensure consistent purity levels for reliable research outcomes.

Suitable for in vitro studies examining growth hormone release mechanisms and GHRH receptor interactions.

Peptide Specifications

SPECIFICATION	DESCRIPTION
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Formula	C152H252N44O42
Molecular Weight	3367.954 g/mol
CAS Number	863288-34-0
PubChem CID	56841945
Synonyms	Mod GRF 1-29, CJC-1295 no DAC, CJC-1295 without DAC, Modified GRF (1-29), tetrasubstituted GRF (1-29)
Purity	≥99% (HPLC)
Solubility	Soluble in BAC water
Storage Conditions	Store at ≤4°C, tightly sealed, away from heat and moisture
Physical Appearance	White lyophilized powder
Shelf Life	36 months from date of manufacture when stored properly
Quality Verification	Third-party tested by certified laboratory
Manufacturing Standard	USA-made, pharmaceutical-grade, GMP compliant
Intended Application	In vitro research applications only

Our Product Quality Guarantee

Every Limitless Biotech compound undergoes independent testing for endotoxins and sterility, meeting rigorous research standards through our systematic quality protocols and proactive manufacturing processes.

Buy Modified GRF 1-29 (CJC-1295 without DAC) From Limitless Biotech

Limitless Biotech provides USA-manufactured peptides with verified molecular sequences and purity through comprehensive third-party testing. We ensure research quality with same-day shipping and dedicated customer support for your scientific endeavors.

Legal Disclaimer

This product is sold as a pure compound for research purposes only and is not meant for use as a dietary supplement. Please refer to our terms and conditions prior to purchase.

Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.

The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.

Research

Modified GRF 1-29 (CJC-1295 without DAC) is a synthetic analog of growth hormone-releasing factor (GHRF) designed to enhance stability and prolong activity. It is a tetrasubstituted analog of hGRF(1-29) with a maleimidopropionamide group at the C-terminus. This modification enables covalent binding to plasma proteins, particularly serum albumin, which significantly extends half-life and bioactivity compared to unmodified GRF 1-29.

Enhanced Stability

CJC-1295 demonstrates enhanced in vitro stability against enzymatic degradation, particularly by dipeptidylpeptidase-IV, and maintains bioactivity in growth hormone (GH) secretion assays[1].

Growth Hormone Release and IGF-1 Axis Modulation

CJC-1295 demonstrates potent effects on the GH/IGF-1 axis through multiple mechanisms. Research shows increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and IGF-1 concentrations by 1.5- to 3-fold for 9-11 days[2]. The peptide specifically increases basal (trough) GH levels by 7.5-fold while preserving natural pulsatile secretion patterns[3].

Importantly, CJC-1295 preserves GH pulsatility while providing sustained elevation. The frequency and magnitude of GH secretory pulses remain unaltered, but the marked enhancement of trough GH levels contributes to overall increased GH secretion and IGF-1 production. This mechanism suggests that continuous GHRH stimulation primarily affects basal GH secretion rather than disrupting normal pulsatile patterns[3].

Growth and Body Composition

Animal studies show effects on growth and body composition parameters. In GHRH knockout mice, CJC-1295 normalized body weight and length, with animals receiving daily treatment exhibiting normal body weight, femur and tibia length, and body composition. The peptide also increased total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation[4].

Neurological and Cognitive Research

Research into neurological applications of GHRH analogs suggests potential neuroprotective effects. Studies indicate that GHRH analogs may demonstrate anxiolytic and antidepressant-like effects through modulatory effects on monoaminergic signaling, inflammatory and oxidative status[5].

The growth hormone/IGF-1 axis plays important roles in brain function and neuroplasticity. IGF-1 specifically contributes to neuronal survival, synaptic plasticity, and cognitive function[6].

Potential In Vitro Applications

RESEARCH APPLICATION	MECHANISM OF ACTION	RESEARCH MODEL
Growth Hormone Secretion Studies	Investigation of GHRH receptor binding, cAMP signaling cascades, and pituitary somatotroph cell GH release patterns	Pituitary Cell Cultures
IGF-1 Axis Modulation	Analysis of downstream GH effects on IGF-1 production, IGF-binding protein expression, and growth factor signaling pathways	Hepatocyte Cultures
Protein Stability Research	Studies on albumin binding kinetics, DPP-IV resistance, and peptide degradation pathways in biological media	Enzymatic Assays
Neuronal Signaling Pathways	Research on neuroprotective mechanisms, monoaminergic modulation, and growth factor effects on neuronal survival	Neuronal Cell Cultures
Anabolic Signaling Cascades	Investigation of growth-promoting pathways, protein synthesis regulation, and cellular proliferation mechanisms	Multi-cell Co-cultures

Research applications shown are intended as examples for in vitro laboratory use only.

References

Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., Van Wyk, P., Pham, K., & Bridon, D. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology, 146 7, 3052-8 . https://doi.org/10.1210/EN.2004-1286.
Teichman, S., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 91 3, 799-805 . https://doi.org/10.1210/JC.2005-1536.
Ionescu, M., & Frohman, L. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of clinical endocrinology and metabolism, 91 12, 4792-7 . https://doi.org/10.1210/JC.2006-1702.
Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291 6, E1290-4 . https://doi.org/10.1152/AJPENDO.00201.2006.
Recinella, L., Chiavaroli, A., Orlando, G., Ferrante, C., Marconi, G. D., Gesmundo, I., Granata, R., Cai, R., Sha, W., Schally, A. V., Brunetti, L., & Leone, S. (2020). Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific reports, 10(1), 732. https://doi.org/10.1038/s41598-019-57292-z.
Sonntag, W. E., Deak, F., Ashpole, N., Toth, P., Csiszar, A., Freeman, W., & Ungvari, Z. (2013). Insulin-like growth factor-1 in CNS and cerebrovascular aging. Frontiers in aging neuroscience, 5, 27. https://doi.org/10.3389/fnagi.2013.00027.

COA

Report for 99%+ grade

Test Report #44329

Test Report #44322

Test Report #44323

COA_CJC-1295_noDAC_10mg_1189-69 vial2_2024-10-07

Endotoxin Gel Clot Assay Report_CJC-1295 (No Dac)_5mg_114242US_2-14-25_Limitless

Additional information

Options	10mg , 5mg
lyophilized	lyophilized – 99%+ , lyophilized – 98.5%+

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 5mg”

Shipping & Delivery

CJC-1295 5mg